Top

Journal of Neurology

Published in:

01-10-2018 | Letter to the Editors

Paradoxical elevation of plasma dabigatran after reversal with idarucizumab in stroke thrombolysis

Authors: Satoshi Hosoki, Masahito Takagi, Hiroshi Yamagami, Daisuke Ando, Kazunori Toyoda, Masatoshi Koga

Published in: Journal of Neurology | Issue 10/2018

Excerpt

Dear Sirs, …

Pollack CV, Reilly PA, van Ryn J et al (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511–520. https://doi.org/10.1056/NEJMoa1707278 CrossRefPubMed

Toyoda K, Iguchi Y, Koga M et al (2018) Consensus guidelines on stroke thrombolysis for anticoagulated patients from Asia: application to other populations. Jpn J Stroke 40:123–135. https://doi.org/10.3995/jstroke.10597 CrossRef

Touzé E, Gruel Y, Gouin-Thibault I et al (2018) Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants. Eur J Neurol 25:747–752. https://doi.org/10.1111/ene.13582 CrossRefPubMed

Eikelboom JW, Quinlan DJ, Van Ryn J, Weitz JI (2015) Idarucizumab the antidote for reversal of dabigatran. Circulation 132:2412–2422. https://doi.org/10.1161/CIRCULATIONAHA.115.019628 CrossRefPubMed

Glund S, Stangier J, Schmohl M et al (2015) Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 386:680–690. https://doi.org/10.1016/S0140-6736(15)60732-2 CrossRefPubMed

Yasaka M, Ikushima I, Harada A et al (2017) Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study. Res Pract Thromb Haemost 1:202–215. https://doi.org/10.1002/rth2.12029 CrossRefPubMedPubMedCentral

Antman EM, Wenger TL, Butler VP et al (1990) Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation 81:1744–1752. https://doi.org/10.1161/01.CIR.81.6.1744 CrossRefPubMed

Title: Paradoxical elevation of plasma dabigatran after reversal with idarucizumab in stroke thrombolysis
Authors: Satoshi Hosoki
Masahito Takagi
Hiroshi Yamagami
Daisuke Ando
Kazunori Toyoda
Masatoshi Koga
Publication date: 01-10-2018
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 10/2018
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-018-9011-8

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Paradoxical elevation of plasma dabigatran after reversal with idarucizumab in stroke thrombolysis

Excerpt

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2018

Scribonius Largus (probably before 1CE–after 48CE)

Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson’s disease dementia, dementia with Lewy bodies and Alzheimer’s disease

Stroke recurrence and mortality in northeastern Greece: the Evros Stroke Registry

Relationship between episodic memory and volume of the brain regions of two functional cortical memory systems in multiple sclerosis

Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients

Does 22q11.2 deletion syndrome contribute to the genetic aetiology of Parkinson’s disease?